World Health Organization

Slides:



Advertisements
Similar presentations
Resource requirements for reaching the treatment goals under PEPFAR XV International AIDS Conference Bangkok July 15, 2004 Owen Smith, Abt Associates Inc.
Advertisements

Scaling up HIV services for women and children achievements and challenges e-lluminate session e-lluminate session Yves Souteyrand 2 March 2010.
TB/HIV Research Priorities in Resource- Limited Settings Where we are now and some suggestions for where to go Paul Nunn February 2005.
Group III: Demand Forecasting
National PSM Coordination Mechanism Dr Vincent Habiyambere WHO/HIV Department AIDS Medicines & Diagnostics Service (AMDS) Bangkok, July 2005.
THE INTERNATIONAL DRUG PURCHASE FACILITY-UNITAID Michel D. Kazatchkine, Ministère des Affaires Etrangères, France.
The 2013 Consolidated WHO Guidelines on ARV Use: Implementing to Achieve Maximum Impact Gottfried Hirnschall, MD, MPH Director, HIV/AIDS Department, WHO.
"3 by 5" progress December 2005 Progress on global access to HIV antiretroviral therapy | 12 April |2 | Antiretroviral therapy coverage in low-
WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies
Partnerships for PMTCT in Uganda A presentation to the IAS conference AVSI Side Event - Washington 25 July 2012 May Anyabolu Deputy Representative UNICEF.
Pre Tender Meeting UNICEF Supply Division, December 2008 Rob Matthews UNICEF Vaccine Procurement for Developing Countries.
The Role of the IATT Optimal Paediatric ARV Formulary and Considerations for New Product Introduction Nandita Sugandhi, M.D. Clinton Health Access Initiative.
Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.
Affordability of HIV/AIDS treatment in developing countries: modeling ARV drug price determinants for a better understanding of the market functioning.
Wish list for design of Paediatric formulations Young Children Syrups reserve for < 10-15kg –No need refrigeration –Stability data for longstorage times,
Global Fund – PEPFAR Coordination The Tanzania Example Dr. Fatma Mrisho Chairperson TACAIDS.
Measles Partnership Meeting Yalda Momeni September 23 rd - WDC.
One SADC, One Vision, One Way Working Together Towards MDG 6: SADC’s Common Vision Hon. Benedict Xaba, Minister of Health of Swaziland International AIDS.
Using the levy in order to finance recurring expenditures : the case of the International Drug Purchase Facility-UNITAID Meeting of experts on the solidarity.
Washington D.C., USA, July 2012www.aids2012.org Lessons from the Rapid Response of Namibia’s Supply Chain When Antiretroviral Treatment Guidelines.
Experience with common basket for ARV procurement Tanzania Emma Lekashingo Msuya.
WHO-HIV Department Strategic Information Unit AIDS Medicines and Diagnostics Service Contribution to Access to medicines Technical Briefing Seminar, November.
What do we mean with ‘ there is no access to Paediatric ARV Formulations ’ ?
2004: 39.4 (35.9 – 44.3) million Western & Central Europe [ – ] North Africa & Middle East [ – 1.5 million] Sub-Saharan.
Affordability of HIV/AIDS treatment in developing countries: an analysis of ARV drug price determinants Luis Sagaon Teyssier; Yves Arrighi; Boniface Dongmo.
AIDS Medicines and Diagnostics Services - a network of organizations supporting access to HIV medicines and diagnostics J. Perriëns.
World Health Organization "3 by 5" Target Treat 3 million by 2005.
Access to Paediatric ARV Formulations Provisions for Children.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Impact of Early Infant Diagnostic (EID) Testing for HIV Exposed Infants in Namibia Dr. Ndapewa Hamunime (MOHSS) Dr. Andreas Shiningavamwe (NIP) Republic.
Nov 2004Access to Paediatric ARV formulations ENSURING SECURE and RELIABLE SUPPLY and DISTRIBUTION SYSTEMS in DEVELOPING COUNTRIES, in the CONTEXT OF HIV/AIDS.
1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Page 0 UNITAID  Melbourne, Australia 2014 Overview of paediatric antiretroviral market : is market in shape to enable achieving targets? Carmen Pérez.
IMPROVING ACCESS AND INNOVATION IN HIV THROUGH VOLUNTARY LICENSING: THE EXPERIENCE OF THE MEDICINES PATENT POOL ICASA – Harare, Zimbabwe Session on Innovation.
Scaling-up Access to Paediatric ART in India Dr. B B Rewari National AIDS Control Organisation India XVII International AIDS Conference Mexico City, 7.
Outcome of a Prevention of mother to child transmission (PMTCT ) programme following Implementation of prophylaxis for HIV infected pregnant women in Barbados:
UNITAID actions and main achievements Investing in the quality of medicines XVII International AIDS Conference Satellite Forum WHO – Essential Medicines.
NEXT STEPS IN THE GLOBAL TREATMENT SIMPLIFICATION AGENDA THE ROLE OF PARTNERSHIPS Nathan Ford Department HIV and Global Hepatitis Programme WHO, Geneva.
The 2013 treatment guidelines and key implementation challenges Martina Penazzato IATT Normative Guidance Advisor HIV Department, WHO (Geneva, Switzerland)
The HIV Response Where are we now?
Contents Global impact 2.Service cascade 3. Policies and WHO support.
OVERVIEW OF PREVENTING MOTHER TO CHILD TRANSMISSION OF HIV
HIV and AIDS The management of HIV and AIDS is an ongoing challenge for Anglo companies operating in countries with a high burden of HIV disease Strategy.
Characterizing the South Africa ART Market
WHO Global Price Reporting Mechanism, the importance of data registration for the regulation of antiretrovirals (ARV) and PSM issues related to access.
Abstract #: WEAD0203 Estimating the size of the pediatric ARV market in 27 low- and middle-income countries (LMICs) through 2025 as PMTCT initiatives continue.
Expanding ARV treatment in developing countries: Issues and Prospects
Drug Pricing Policies and Challenges
Measles Containing Vaccines
Children & AIDS Statistical Update 2017.
Closing the Treatment Gap of Children Living with HIV
Yellow Fever Vaccine Tender
"3 by 5" progress December 2005.
B. Dongmo Nguimfack AMDS TCO Unit/HIV, WHO
Overview of the AMDS Products
The role of CD4 in patient monitoring Amsterdam July 2018
Thokozani Kalua MBBS MSc Malawi Ministry of Health
Spending More to Spend Less
International Treatment Preparedness Coalition (ITPC)
AMDS Products, events and issues.
Serge Masyn Director, Johnson & Johnson Global Public Health
Gaps & obstacles Priorities & Solutions
July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.
AIDS-related deaths the lowest this century
Demand Forecasts for for HIV/AIDS ARV formulations
Key Affected Populations
Forecasting for ARVs medicines
SETTING TARGETS TO DRIVE DECISIONS MAKING AND ACOUNTABILITY
Contents Global impact 2.Service cascade 3. Policies and WHO support.
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

World Health Organization Demand for ARV medicines in low and middle income countries will exceed 16 million person-years by the end of 2016 V. Habiyambere, J. Perriëns, B. Dongmo-Nguimfack, World Health Organization On behalf of the ARV Forecasting Technical Working Group UNAIDS, CHAI, UNICEF, Global Fund, PEPFAR (SCMS, USAID), and Futures Institute Thank you Mr Chairman – When we submitted this abstract we gave it a bit of a headline title – a bit bold – yet: we mean it. I work for the world health organization, but the work I'm presenting today is the fruit of a collaboration with UNAIDS, CHAI, UNICEF, the Global Fund, PEPFAR, and the Futures Institute. They collaborate with us in the ARV forecasting technical working group - and have done so for the last 6 years. We are grateful for their continuing collaboration. Background: In 2013, the global capacity to supply tenofovir and efavirenz has come under strain. To ensure that enough ARVs are produced globally, WHO convened a global ARV Forecasting Technical Working Group, with UNAIDS, CHAI, UNICEF, Global Fund, PEPFAR, and Futures Institute to develop annual 3-year forecasts of the demand of ARVs since 2005. The forecasts for 2013 to the end of 2016 are presented. Methods: Forecast based on 1) annual WHO survey on ARV use, 2) volume of individual ARVs in the global procurement reporting mechanism, 3) CHAI projections for 22 high volume countries, 4) Global Fund and PEPFAR/SCMS quantification data, and 5) projected evolution of ART needs from UNAIDS and the Futures Institute. Three forecast scenarios were used and averaged arithmetically to generate the projected demand. Forecasts were broken down by active ingredient and adults vs. children. Results: Demand of ART will increase from 11.5 million (M) person-years (PYR) by end 2013 to 15.0 M by end 2015 and 16.8 M by end 2016. By 2016, the projected demand will be 15.7 M PYR of adult and 1.1 M PYR of paediatric formulation. Demand for paediatric ART will continue well beyond. The market share of tenofovir will increase from 50% in 2013 to reach 62% in 2016, that of AZT will decrease from 40% to 34 % and that of d4T will decrease from 8% to 2%. That of EFV will increase from 48% in 2013 to 63%, and NVP will gradually lose market share. Second line ART uptake will increase slowly from 4.4% now to 5.0% in 2016. Insufficient amounts of data were available to project the uptake of third line drugs. Conclusions: Scale up of ART will reach 15 M by 2015 and continue beyond. Meeting demand is a challenge, which requires reliable forecasts of future ARV demand which WHO and its technical partners will continue to produce.

WHY ? ART demand increases year by year production capacity needs to keep pace with demand Global supply security is an issue 2013: TDF and EFV 2014: d4T/3TC pediatric formulation outage; ZDV Manufacturers need independent assessment of what and how much to produce 2-3 years ahead of time We started our collaboration because ART demand increases year by year, and we wanted to be sure that production capacity needs to keep pace with demand. Global supply security is an issue In 2013 we had a supply crush for TDF and EFV This year 2014 we have a global supply outage for d4T/3TC pediatric formulation and a ZDV supply crush To be able to supply the right ARVs on time, manufacturers need independent assessment of what and how much to produce 2-3 years ahead of time, certainly when they need to bring new formulations to the market.

Methods – forecast of total future demand 3-year linear projection of ARV use in annual Global AIDS reporting Limited to 80% of total number of people needing treatment, from UNAIDS/Futures Institute, according to WHO 2013 criteria Arithmetic average 3-year extrapolation of country targets stated in annual WHO survey 3-year linear extrapolation 22 country quantifications by CHAI This slide shows how we derived the forecast of global ARV demand: We made a linear extrapolation of the number of people on treatment from the UNAIDS Global Aids Reporting, from treatment targets which countries communicated to us in an annual survey, and from quantifications by CHAI in 22 countries. To cover countries for which we had no data we extrapolated the trends per region. We limited the number treated in each country to 80% of those eligible for treatment using WHO 2013 criteria. And we then made an arythmetic average of the 3 extrapolations to generate point estimates of the number of people treated in future years. Finally we stratified our estimates by adults and children. Stratification: adult/paediatric ARV use

Total future demand This is what this looks like. In blue the observed scale up – beyond are our forecasts – and I`ll zoom into those next.

Total future demand The forecast of 16.8 million people on treatment at the end of 2016 is the average of the 18.5 from the country targets, the 16.1 of the number treated from UNAIDS/WHO global AIDS ereporting, and the 15.7 from the Clinton Foundation estimates. The average estimate for end of 2013 was 11.5 – when in reality 11.7 were reached. In the 6 years in which we produced our forecasts we have consistently underestimated the future treatment uptake be about 2%. We therefore believe that the 15 by 15 target will be met, and think that it will in fact be exceeded.

Forecast of adult/paediatric and first/second line treatment (country targets) This slide shows you how this breaks down into adult and pediatric treatment, and between first and second line treatment. First note that over the forecasting horizon we see little movement in the uptake of second line treatment – stuck at about 5% on average. Access to VL to diagnose treatment failure might change it, but its roll out is still to timid to bring about a landslide in treatment use. Second, in spite of the increasing uptake of PMTCT interventions, the number of children on treatment is not decreasing in the near future as infected children will continue to joint the pool of treated children. Over a longer time horizon there will likely be a decrease.

Methods – forecasts of market share Annual WHO survey – 16 countries reporting in each year since 2010 Arithmetic Average Global Price Reporting Mechanism – 75% of LMIC procurement lagged 1 year CHAI 21 country 5-year projections PEPFAR 2-3 year quantification - 15 countries Global Fund quantification – 54 countries in 2014 and 30 in 2015 We then proceded to forecast the market share of individual ARVs. The data considered for this are the Annual WHO survey, the WHO global price reporting mechanism (which records around 75% of all RV sales to LMIC), the CHAI projections, and quantifications by PEPFAR and the Global Fund. The share of each molecule in those databases is determined, and averaged.

Share of d4T in adult treatment How this works is illustrated on this slide - which shows the decreasing uptake of d4T. Of note is that all sources indicate the same trend – but that d4T is not expected to disappear totally: some will still be used when people cannot tolerate other ARVs.

Share of ZDV, TDF, d4T in adult treatment This shows the average of the trends predicted for ZDV, TDF and d4T - with TDF going up, and ZDV going down – perhaps a but slower than expected.

Share of EFV, NVP, LPV and ATV in adult treatment Here is the predicted market share of NNRTI and PI's in adult treatment – EFV replacing NVP, and ATV nibbling at the market share of LPV.

Limitations and next steps Overlap between data sets Limited time horizon No insight on formulation use New molecules not included We will expand time horizon to 5 – 7 years Will drill down to formulation level

But the bottom line is: We are on track for 15 million by 2015 New drugs are being introduced and older ones are disappearing Without significant impact on the cost of ART in LMIC More on access to ARV drugs (price, regulatory status, API, forecast of use, issues in MIC) on: http://www.who.int/hiv/amds/en/